Avanafil
As of the edition of 20 October 2026, Avanafil is a small molecule: marketed, first approved in 2012 (US); acts on PDE5A; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Stendra
- First approved
- 27 April 2012 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Phoenix; 2 holders in all
- Registered trials
- 21, 0 stopped early
- Disease areas
- Mental health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Avanafil.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | O76074 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 11 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 6 | 6 | 0 | 0 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 21 |